Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | EPOR | P19235 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19155468 | 0.86 | TSHR (0.50) | TSHRHPGDSMN1; SMN2GLP1RCNR1 | |
| SCHEMBL23320108 | 0.85 | TSHR (0.47) | TSHRHPGDSMN1; SMN2GLP1RCNR1 | |
| SCHEMBL24253269 | 0.85 | TSHR (0.47) | TSHRHPGDSMN1; SMN2GLP1REPOR | |
| SCHEMBL23320105 | 0.84 | CASP2 (0.46) | CNR1LMNAPKMCASP2NAMPT | |
| SCHEMBL12312753 | 0.84 | SMN1; SMN2 (0.55) | TSHRHPGDSMN1; SMN2LMNAPKM | |
| SCHEMBL25978308 | 0.84 | TSHR (0.51) | TSHRHPGDSMN1; SMN2GLP1RCNR1 | |
| SCHEMBL23334540 | 0.84 | TSHR (0.51) | TSHRHPGDSMN1; SMN2CNR1LMNA | |
| SCHEMBL25793735 | 0.83 | HPGD (0.40) | TSHRHPGDSMN1; SMN2GLP1RCNR1 | |
| SCHEMBL16159250 | 0.83 | TSHR (0.70) | TSHRHPGDSMN1; SMN2CNR1LMNA | |
| SCHEMBL25793668 | 0.83 | CASP2 (0.47) | CNR1LMNAPKMCASP2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634450-B2 | DOT1L degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20210130386-A1 | DOT1L DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130386-A1 | DOT1L DEGRADERS AND USES THEREOF | CRBN, CUL1, STUB1 | TSHR 3358/4885HPGD 4011/4885SMN1; SMN2 1538/4885 |
| US-11634450-B2 | DOT1L degraders and uses thereof | CRBN, CUL1, STUB1 | TSHR 3358/4885HPGD 4011/4885SMN1; SMN2 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.